Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.45 |
| ▸ | EED | O75530 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30360690 | 1.00 | KDM4C (0.46) | KDM4CMTNR1AEEDLMNAL3MBTL1 | |
| SCHEMBL3366209 | 0.87 | MTNR1A (0.59) | MTNR1AKDM4E | |
| SCHEMBL29907252 | 0.84 | EED (0.46) | KDM4CMTNR1AEEDLMNAL3MBTL1 | |
| SCHEMBL506237 | 0.84 | EED (0.46) | KDM4CMTNR1AEEDLMNAL3MBTL1 | |
| SCHEMBL8096405 | 0.81 | EED (0.44) | KDM4CMTNR1AEEDLMNAABCG2 | |
| SCHEMBL11044001 | 0.81 | EED (0.44) | KDM4CMTNR1AEEDLMNAL3MBTL1 | |
| SCHEMBL19772837 | 0.81 | MTNR1A (0.45) | KDM4CMTNR1AEEDLMNAABCG2 | |
| SCHEMBL7771835 | 0.81 | KDM4C (0.46) | KDM4CMTNR1AEEDLMNAABCG2 | |
| SCHEMBL1010010 | 0.81 | TAAR1 (0.46) | KDM4CMTNR1AEEDABCG2HTR2A | |
| SCHEMBL166877 | 0.79 | KDM4C (0.51) | KDM4CMTNR1AEEDLMNAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4464317-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Sumitomo Pharma America, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3494119-B1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-11958862-B2 | Compounds and compositions and uses thereof | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| CN-116514761-A | Compounds, compositions and uses thereof | 赛诺维信制药公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116283877-A | Compounds, compositions and uses thereof | 赛诺维信制药公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110088107-B | Compounds, compositions and uses thereof | 赛诺维信制药公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20220340588-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-27 | — | — | US | disclosed |
| US-10927124-B2 | Compounds and compositions and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-1673088-A1 | 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1583745-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005030213-A1 | 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | disclosed |
| WO-2004063163-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-0661271-B1 | AZEPINE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS SIGMA-RECEPTOR LIGANDS | ASAHI CHEMICAL IND (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-5817822-A | ANTITUOR, ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | NOVARTIS CORPORATION (US) | 1998-10-06 | — | — | US | disclosed |
| US-5658923-A | USED IN TREATING DISEASES RELATED TO SIGMA-RECEPTOR, SUCH AS SCHIZOPHRENIA | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1997-08-19 | — | — | US | disclosed |
| EP-0661271-A1 | AZEPINE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | KDM4C 3620/4885MTNR1A 472/4885EED 2429/4885 |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | KDM4C 3801/4885MTNR1A 87/4885EED 4148/4885 |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ADH1C, HTR6, CNR1 | KDM4C 751/4885MTNR1A 235/4885EED 3519/4885 |
| US-10927124-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | KDM4C 3620/4885MTNR1A 472/4885EED 2429/4885 |
| US-11958862-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | KDM4C 3620/4885MTNR1A 472/4885EED 2429/4885 |
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | KDM4C 3893/4885MTNR1A 76/4885EED 4244/4885 |
| US-20220340588-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | KDM4C 3620/4885MTNR1A 472/4885EED 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.